发现,优化和评估非核酸性SARS-CoV-2 NSP14抑制剂
Michael W Miller1, Cindy Meyer2, Aitor Garzia2
1Sanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Journal of medicinal chemistry
|September 5, 2025
概括
我们发现了TDI-015051,一种针对SARS-CoV-2的小分子抑制剂
科学领域:
- 病毒学
- 医学化学
- 药物发现
背景情况:
- SARS-CoV-2 非结构蛋白14 (NSP14) 对于病毒RNA合成至关重要.
- NSP14的关氨酸-N7甲基转移酶活性是抗病毒疗法的潜在目标.
- 抑制病毒甲基转移酶提供了一种新的抗病毒策略.
研究的目的:
- 识别和描述SARS-CoV-2 NSP14的小分子抑制剂.
- 验证SARS-CoV-2 NSP14作为COVID-19治疗的药物标.
- 为了证明病毒甲基转移酶的药理抑制.
主要方法:
- 进行了结构-活性关系 (SAR) 研究.
- 高通量选 (HTS) 确定了最初的结果.
- 使用热转移测定和X射线结晶学来分析抑制剂结合.
主要成果:
- 开发出具有单位纳米细胞活性的强有力的非核酸抑制剂.
- 建立并验证了抑制三元复合体 (NSP14,SAH,抑制剂) 的模型.
- 概念验证研究证实NSP14是一种可行的药物标.
结论:
- SARS-CoV-2 NSP14是COVID-19的一种有效药物标.
- 药理上抑制病毒甲基转移酶是一种有前途的抗病毒治疗方法.
- TDI-015051代表了SARS-CoV-2 NSP14的第一类抑制剂.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
15.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.8K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K


